Sodium o-iodohippurate | 51888-80-3

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Sodium o-iodohippurate
• 英文别名: sodium;2-[(2-iodobenzoyl)amino]acetate
• CAS: 51888-80-3；133-17-5
• 化学式: C9H7INNaO3
• 分子量: 327.05
• InChiKey: XYITYKDGJLHYPW-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.23
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  69.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Sodium o-iodohippurate 、 碘化钠 、 氯化亚铜 、 盐酸 生成 1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dipentyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)pyrimidin-2,4(1H,3H)-dione
  参考文献：
  名称：

  ROCKSTROH, K.;TEICH, A., ISOTOPENPRAXIS, 23,(1987) N 11, 411-414

  摘要：

  DOI：

文献信息

• Radiolabelled metallocene derivatives
  申请人：Mallinckrodt Diagnostica (Holland) B.V.

  公开号：EP0113135A2

  公开（公告）日：1984-07-11

  The invention relates to radiolabelled metallocene derivatives of the general formula wherein Me is a metallocenyl group with a radioactive central atom, R is a carbonyl or methylene group, R, is a hydrogen atom or an alkyl group having 1-4 carbon atoms, A is a carboxy group or a pharmaceutically acceptable salt thereof, or an alkoxycarbonyl or alkanoyl group having 2-5 carbon atoms, and n is 1 - 4. The invention also relates to radiodiagnostic compositions comprising said radiolabelled metallocene derivatives and to a method of performing a radiodiagnostic examination, in particular of examining the renal function.

  本发明涉及通式的放射性标记茂金属衍生物，其中 Me 是具有放射性中心原子的茂金属基，R 是羰基或亚甲基，R，是氢原子或具有 1-4 个碳原子的烷基，A 是羧基或其药学上可接受的盐，或具有 2-5 个碳原子的烷氧羰基或烷酰基，n 是 1 - 4。本发明还涉及包含上述放射性标记茂金属衍生物的放射性诊断组合物，以及进行放射性诊断检查，特别是检查肾功能的方法。
• Method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radioiodinated, aromatic or heteroaromatic compound, as well as a kit for preparing a diagnostic composition on the basis of this compound
  申请人：MALLINCKRODT, INC.(a Missouri corporation)

  公开号：EP0165630A2

  公开（公告）日：1985-12-27

  The invention relates to a method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radio-iodinated aromatic or heteroaromatic compound, in which the (hetero)aromatic nucleus optionally comprises one or more additional substituents, by reacting the corresponding halogenated or diazonium-substituted compound in the presence of a water-soluble acid and of copper ions as a catalyst with a likewise water-soluble chloride, bromide radiobromide, iodide or radio-iodide, in which the reaction is carried out in the presence of one or more reduction agents, which are stable in acid medium, in a quantity exceeding the quantity of catalyst. The invention also relates to a composition suitable for diagnostic examination and to a kit for the preparation thereof. The invention further relates to a method and an equipment for the preparation of said composition.

  本发明涉及一种制备氯化、溴化、放射性溴化、碘化和/或放射性碘化芳香族或杂芳香族化合物的方法，其中（杂）芳香族核可选择地包括一个或多个附加取代基、在水溶性酸和作为催化剂的铜离子存在下，使相应的卤代或重氮代化合物与同样的水溶性氯化物、溴化物、放射性溴化物、碘化物或放射性碘化物反应，其中反应是在一种或多种在酸介质中稳定的还原剂存在下进行的，还原剂的数量超过催化剂的数量。本发明还涉及一种适用于诊断检查的组合物及其制备试剂盒。本发明还涉及制备上述组合物的方法和设备。
• Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
  申请人：Schering AG

  公开号：EP1462119A1

  公开（公告）日：2004-09-29

  The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of cancer disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis of radiopharmaceutics into cells of the kidney and the subsequent radioinduced damaging of the kidney catabolism by blocking or interfering with the association or binding of radiotherapeutics and/or radiodiagnostics to the receptor megalin, a member of the LDL-receptor family. In another aspect of the present invention, the expression of megalin is altered, in order to prevent the endocytosis and cellular internalisation of radiopharmaceutics into cells of the kidney.

  本发明广泛涉及癌症疾病的治疗、诊断和预防。更具体地说，本发明涉及通过阻断或干扰放射性治疗药物和/或放射性诊断药物与受体megalin（低密度脂蛋白受体家族的成员）的结合或结合，防止放射性药物内吞进入肾脏细胞以及随后放射性诱导的肾脏分解代谢损伤的方法和组合物。本发明的另一个方面是改变megalin的表达，以防止放射性药物内吞和细胞内化到肾脏细胞中。
• Pharmaceutical combination comprising adenosine A1 receptor antagonists and radiocontrast media
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1870093A1

  公开（公告）日：2007-12-26

  The present invention relates to pharmaceutical combinations comprising a therapeutically effective amount of at least one selective adenosine A1 antagonist combined with at least one radiocontrast media. The invention also relates to the use of said combinations in the manufacture of a medicament for the treatment of radiocontrast media induced nephropathy. Furthermore, the invention is relating to a kit comprising a single dosage form of said combination of at least one adenosine A1 antagonist and at least one radiocontrast media.

  本发明涉及由治疗有效量的至少一种选择性腺苷 A1 拮抗剂与至少一种放射性造影剂组合而成的药物组合物。本发明还涉及使用所述组合物制造治疗放射性造影剂诱发的肾病的药物。此外，本发明还涉及一种试剂盒，该试剂盒包含上述至少一种腺苷 A1 拮抗剂和至少一种放射造影剂组合的单一剂型。
• Setting of hardenable bone substitute
  申请人：BONE SUPPORT AB

  公开号：US10294107B2

  公开（公告）日：2019-05-21

  The invention relates to hardenable ceramic bone substitute compositions having improved setting, powders for such compositions and methods for their manufacture and use in medical treatment. More specifically the invention relates to hardenable bone substitute powder and hardenable bone substitute paste with improved setting properties, comprising calcium sulfate and heat-treated hydroxyapatite (passivated HA), which bone substitute is suitable for treatment of disorders of supportive tissue such as bone loss, bone fracture, bone trauma and osteomyelitis.

  本发明涉及具有更好凝固性的可硬化陶瓷骨替代物组合物、这种组合物的粉末及其制造方法和在医疗中的使用。更具体地说，本发明涉及由硫酸钙和经热处理的羟基磷灰石（钝化 HA）组成的具有更好凝固特性的可硬化骨替代物粉末和可硬化骨替代物浆料，这种骨替代物适用于治疗骨质疏松、骨折、骨创伤和骨髓炎等支撑组织疾病。